Abstract:4577 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Though biannual ultrasound surveillance with or without alpha-fetoprotein (AFP) testing is recommended for at-risk patients, its sensitivity for early-stage HCC detection is suboptimal. We therefore evaluated performance of a biomarker panel incorporating methylated DNA markers (MDMs) and proteins for early HCC detection in at-risk patients with chronic liver disease. Methods: In an international, multicenter, case-control study, blood specimens were collected from patients with HCC per AASLD criteria and controls matched for age and liver disease etiology. All patients had underlying cirrhosis or chronic HBV infection. Whole blood was collected in cell-free DNA stabilizing and serum-separation tubes and shipped to a central laboratory for processing. The levels of 5 MDMs, AFP, and AFP-L3 were assessed along with age and sex. We used 537 samples in a 5-fold validation for developing a LASSO regression algorithm to classify samples as HCC positive or negative. Model robustness was tested by perturbing the data in silico and analyzing results with the predictive algorithm. Algorithm performance was compared to AFP alone and the GALAD score (Gender, Age, AFP-L3, AFP, and DCP). Results: The study included 136 HCC cases (81 early-stage—BCLC stage 0/A) and 401 controls. With specificity set at 89%, we developed a model using sex, AFP, and 3 MDMs (HOXA1, TSPYL5, B3GALT6) with higher sensitivity (70%) for early-stage HCC compared to GALAD (54%) or AFP (31% at 20 ng/mL or 52% at ≥7.7 ng/mL) (Table). The AUC for the HCC marker panel was 0.91 (95% CI 0.89 – 0.94) compared to GALAD (0.88; 95% CI 0.85 – 0.91) or AFP (0.84; 95% CI 0.81 – 0.87). The panel performed similarly in viral (AUC = 0.94) and non-viral (AUC = 0.89) etiologies. Conclusions: The robust algorithm based on novel blood-based biomarkers presented here provides higher sensitivity for early-stage HCC compared to other available blood-based biomarkers and, therefore, could significantly impact HCC clinical management and patient outcomes. Further clinical studies to validate the algorithm are ongoing. Clinical trial information: NCT03628651 . Performance of HCC marker panel. Sensitivity % (95% CI) Specificity % (95% CI) All-Stage AUC (95% CI) Early-Stage All-Stage Current HCC marker panel 70 (60 – 80) 81 (74 – 87) 89 (86 – 92) 0.91 (0.89 – 0.94) GALAD 54 (43 – 65) 68 (59 – 75) 89 (86 – 92) 0.88 (0.85 – 0.91) AFP (≥7.7 ng/mL) 52 (41 – 63) 64 (56 – 72) 89 (86 – 92) 0.84 (0.81 – 0.87) AFP (20 ng/mL) 31 (21 – 42) 46 (38 – 55) 98 (96 – 99)

Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?

Emerging Biomolecules for Practical Theranostics of Liver Hepatocellular Carcinoma.

Ultrasonography of Hepatocellular Carcinoma: from Diagnosis to Prognosis

Novel Blood-Based Biomarkers for HCC

A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma

Advancing Surveillance Strategies for Hepatocellular Carcinoma: A New Era of Efficacy and Precision

Algorithm for blood-based panel of methylated DNA and protein markers to detect early-stage hepatocellular carcinoma with high specificity.

Novel Biomarkers for Early Detection of Hepatocellular Carcinoma

Advances in the Early Detection of Hepatobiliary Cancers

Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma.

Analytical validation of a novel multi-target blood-based test to detect hepatocellular carcinoma

Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma

New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma

A Blood-Based 22-Gene Expression Signature for Hepatocellular Carcinoma Identification

A Large‐scale, Multicenter Serum Metabolite Biomarker Identification Study for the Early Detection of Hepatocellular Carcinoma

Circulating Biomarkers for the Early Diagnosis and Management of Hepatocellular Carcinoma with Potential Application in Resource-Limited Settings

Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma

Opportunities to address gaps in early detection and improve outcomes of liver cancer

Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis

Biomarkers for Hepatocellular Carcinoma: Progression in Early Diagnosis, Prognosis, and Personalized Therapy

Liquid biopsies for hepatocellular carcinoma